2023 Was a tricky calendar year for the biopharma sector, with quite a few organizations downsizing and restructuring their workforces to stay afloat. There are signs of recovery, as mergers and acquisitions picked up across the pharmaceutical and lifestyle sciences market while in the latter Section of 2023 and also https://sites.google.com/view/bio-sites/blog